Global Follicular Lymphoma Market Insights, Epidemiology and Forecast to 2030 - ResearchAndMarkets.com

·6 min read

The "Follicular Lymphoma - Market Insights, Epidemiology and Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Follicular Lymphoma Market Insights, Epidemiology and Forecast to 2030 delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Follicular Lymphoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Follicular Lymphoma market report provides analysis regarding current treatment practices, and emerging drugs like Tazemetostat (Epizyme, Inc.), Lenalidomide (Celgene Corp.) and CAR-T therapies Kymriah (Novartis) and Yescarta (Kite Pharmaceuticals/Gilead), potential therapies, market share of the individual therapies, historical, current and forecasted Follicular Lymphoma market size from 2017 to 2030 segmented by seven major markets.

The report also covers current Follicular Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Follicular Lymphoma Treatment

This chapter covers the details of conventional and current medical therapies available in the Follicular Lymphoma market for the treatment of the condition. It also provides the country-wise Follicular Lymphoma treatment guidelines across the United States, Europe, and Japan.

Follicular Lymphoma Epidemiology

The Follicular Lymphoma epidemiology chapters provide insights about historical and current Follicular Lymphoma patient pool and forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Follicular Lymphoma epidemiology is segmented by Total incident cases of Follicular Lymphoma, Cases of Follicular Lymphoma by Grade, Cases of Follicular Lymphoma by Age and Stage-specific Follicular Lymphoma cases. The report includes a thorough analysis of all segmentations.

In the US, the cases of Follicular Lymphoma were 14,329 in 2017. Moreover, the grade-specific cases of Follicular Lymphoma were highest among grade I and were reported to be 5,198 in the country.

According to the report analysis, the total prevalent population of Follicular Lymphoma in seven major markets was 33,363 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

Among all the seven major markets, the United States accounts for the highest number of Follicular Lymphoma cases.

Follicular Lymphoma Drug Chapters

Drug chapter segment of the Follicular Lymphoma report encloses the detailed analysis of Follicular Lymphoma pipeline drug. It also helps understand the Follicular Lymphoma clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.

Treatment is focused entirely on the management of symptoms and supporting the health and well-being of the affected child or adult. The management of Follicular Lymphoma revolves around the appropriate therapies for the physical and neurological problems encountered in the condition and provision for the special educational needs, given the precise cognitive profiles and behavioral features of the condition. There are many upcoming mono and combinational therapies such as Tazemetostat (Epizyme, Inc.), Lenalidomide (Celgene Corp.) and CAR-T therapies Kymriah (Novartis) and Yescarta (Kite Pharmaceuticals/Gilead) etc. for the treatment of Follicular Lymphoma in the pipeline.

Follicular Lymphoma Market Outlook

The Follicular Lymphoma market size is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounts for the largest Follicular Lymphoma market size with USD 799 million in 2017, while Spain had the smallest market size of Follicular Lymphoma with USD 56 million in 2017.

Follicular Lymphoma Drugs Uptake

This section focuses on the rate of uptake of the potential drugs in the Follicular Lymphoma market that are expected to get launched in the market during the study period 2017-2030. The analysis covers Follicular Lymphoma market uptake by drugs; patient uptake by therapies; and sale of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of Follicular Lymphoma market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.

Follicular Lymphoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Follicular Lymphoma key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of Follicular Lymphoma collaborations, acquisition and merger, licensing, patent details and other information for Follicular Lymphoma emerging therapies.

Reimbursement Scenario in Follicular Lymphoma

Approaching reimbursement, proactively, can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working in Follicular Lymphoma domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Follicular Lymphoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Report Highlights

  • In the coming years, Follicular Lymphoma market scenario is expected to alter across the 7MM due to the launch of novel therapies with new mechanisms of action considering the high unmet medical need.

  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Follicular Lymphoma Report Insights

  • Patient Population

  • Therapeutic Approaches

  • Follicular Lymphoma Pipeline Analysis

  • Follicular Lymphoma Market Size and Trends

  • Market Opportunities

  • Impact of upcoming Therapies

Follicular Lymphoma Report Key Strengths

  • 11 years Forecast

  • 7MM Coverage

  • Follicular Lymphoma Epidemiology Segmentation

  • Key Cross Competition

  • Highly Analyzed Market

  • Drugs Uptake

Follicular Lymphoma Report Assessment

  • Pipeline Product Profiles

  • Key Products and Key Players

  • Market Drivers and Barriers

Companies Mentioned

  • Epizyme

  • Bayer Healthcare Pharmaceuticals

  • Verastem Oncology

  • Gilead Sciences

  • Xynomic Pharmaceuticals, Inc.

  • TG Therapeutics

  • MEI Pharma

  • Regeneron Pharmaceuticals

  • Incyte Corporation

  • Novartis

  • Kite Pharma

  • Bristol-Myers Squibb

  • Takeda Oncology

  • Merck

  • AbbVie/Genentech

  • Nordic Nanovector ASA

  • Rhizen Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/hnll4

View source version on businesswire.com: https://www.businesswire.com/news/home/20200921005557/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900